Treatment of migraine with monoclonal antibodies.
| Autor: | Serra López-Matencio JM; Hospital Pharmacy Division, Hospital Universitario de La Princesa, Madrid, Spain., Gago-Veiga AB; Neurology Department, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain., Gómez M; Methodology Unit, Health Research Institute Princesa (IIS-IP), Madrid, Spain., Alañón Plaza E; Hospital Pharmacy Division, Hospital Universitario de La Princesa, Madrid, Spain., Mejía GP; Pharmacology Department, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain., González-Gay MÁ; Rheumatology Division, Hospital Universitario Marqués de Valdecilla, University of Cantabria, Santander, Spain., Castañeda S; Rheumatology Division, Hospital Universitario de La Princesa, Madrid, Spain.; Medicine Department, Universidad Autónoma de Madrid (UAM) and Catedra, Madrid, Spain. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Expert opinion on biological therapy [Expert Opin Biol Ther] 2022 Jun; Vol. 22 (6), pp. 707-716. Date of Electronic Publication: 2022 May 13. |
| DOI: | 10.1080/14712598.2022.2072207 |
| Abstrakt: | Introduction: In the few last years, a new family of drugs, anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs), has been developed for migraine therapy. Anti-CGRP mAbs are highly effective, but the current limited experience with their use and their high-cost warrant establishing certain rules of use. Areas Covered: The present review provides an overview of the management of migraine patients, especially those who are undergoing treatment with anti-CGRP mAbs. Expert Opinion: Thanks to new research focused on the pathophysiology of migraine, and the discovery that CGRP plays a key role in its etiopathogenesis, new drugs targeting CGRP have been developed. These drugs have led to a paradigm shift, anticipating new and stimulating possibilities in migraine treatment. While physicians and patients are full of expectation about the advantages of this new family of drugs, there are still obstacles to overcome in order to make the best use of them. It is essential to form multidisciplinary teams that can identify patients who will benefit from these therapies, conducting cost-effective treatments. The follow-up of these therapies in the coming years is paramount due to the lack of experience in the management of these drugs and the peculiarity of disease evolution in migraine patients. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|